FY2022 Q3 Financial and R&D Update

Best change from baseline in target lesion size (%) Change in target lesion from baseline (%) Dato-DXd 100- 50- -50 -100 BEGONIA Study SABCS 2022 Efficacy PD-L1 (TAP 10% cutoff) Low High Missing 240 220 200 180 160- 140 120 100 Best Objective Response Complete response Partial response Stable disease RECIST progression Not evaluable RECIST progression at visit 80 60 40 20 0 -20 40 -60 -80 -100 -120 T 0 12 18 24 30 36 42 48 54 60 66 Time (weeks) BEGONIA (Arm7) Daiichi-Sankyo BEGONIA is open-label platform study to evaluate safety and efficacy of durvalumab combined with other novel therapies in 1L advanced/ metastatic TNBC. Combination of durvalumab and Dato-DXd is evaluated in Arm7 Confirmed ORR was 73.6% in 53 evaluable patients, including 4 (7.5%) CR ■Durable responses with 82% patients remaining in response at the data cut off The most common AEs were nausea, stomatitis, and alopecia Dato-DXd + durvalumab demonstrated a tolerable and manageable safety profile Data Cutoff: July 22, 2022 AES: adverse events, CR: complete response, ORR: objective response rate, RECIST: Response Evaluation Criteria in Solid Tumours, SABCS: San Antonio Breast Cancer Symposium, TNBC: triple-negative breast cancer Results demonstrate a compelling response and support further investigation of combination therapies in 1L advanced/ metastatic TNBC and early stage disease 25

View entire presentation